Journal Article
. 2020 Jun; 50(8):966-977.
doi: 10.1111/hepr.13511.

Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria

Takuya Sho 1 Goki Suda 1 Koji Ogawa 1 Taku Shigesawa 1 Kazuharu Suzuki 1 Akihisa Nakamura 1 Masatsugu Ohara 1 Machiko Umemura 1 Naoki Kawagishi 1 Mitsuteru Natsuizaka 1 Masato Nakai 1 Kenichi Morikawa 1 Ken Furuya 2 Masaru Baba 2 Jun Ito 3 Yoshiya Yamamoto 3 Tomoe Kobayashi 4 Takashi Meguro 5 Akiyoshi Saga 6 Takuto Miyagishima 7 Katsumi Terasita 8 Tomofumi Takagi 8 Toshiya Kamiyama 9 Akinobu Taketomi 9 Naoya Sakamoto 1 
Affiliations
  • PMID: 32562334
  •     34 References
  •     11 citations

Abstract

Aim: This study aimed to determine the efficacy and safety of lenvatinib for patients with unresectable hepatocellular carcinoma (HCC) who did not meet REFLECT eligibility criteria (phase 3 clinical trial).

Methods: In this multicenter retrospective study, patients with unresectable HCC treated with lenvatinib between 2018 and 2019 and had adequate clinical data were included. Objective response rate, progression-free-survival (PFS) and safety were evaluated according to meeting or not meeting the REFLECT eligibility criteria and according to the criteria of the REFLECT trial.

Results: Of the 105 patients included, 61% (64 of 105) did not meet the REFLECT eligibility criteria. Safety and median PFS of lenvatinib were similar between the patients who did and those who did not meet the criteria. Among the patients who did not meet the criteria, 28, 27, 14, six, seven and five had a history of tyrosine kinase inhibitor (TKI) treatment, Child-Pugh score B, HCC in ≥50% of the liver, reduced platelet count, bile duct invasion and main portal vein invasion, respectively. The efficacy and safety of lenvatinib for patients with or without Child-Pugh-score B or HCC in ≥50% of the liver were similar. Although treatment outcome was not significantly different, patients with TKI treatment history tended to have longer median PFS, whereas those with main portal vein invasion tended to have shorter median PFS.

Conclusion: Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria. However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion.

Keywords: HCC; PFS; REFLECT trial; lenvatinib; real world.

Lenvatinib for Hepatocellular Carcinoma: A Literature Review.
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki.
Pharmaceuticals (Basel), 2021 Jan 10; 14(1). PMID: 33418941    Free PMC article.
Review.
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Taku Shigesawa, Goki Suda, +16 authors, Naoya Sakamoto.
PLoS One, 2021 Mar 02; 16(3). PMID: 33647018    Free PMC article.
A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
Angelo Dipasquale, Arianna Marinello, Armando Santoro.
J Hepatocell Carcinoma, 2021 Apr 23; 8. PMID: 33884259    Free PMC article.
Review.
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Akinori Kubo, Goki Suda, +15 authors, Naoya Sakamoto.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298844    Free PMC article.
Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant.
Pil Soo Sung, Ji Won Han, +8 authors, Seung Kew Yoon.
Front Pharmacol, 2021 Jul 31; 12. PMID: 34326770    Free PMC article.
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
Jaejun Lee, Ji-Won Han, +16 authors, Seung-Kew Yoon.
J Clin Med, 2021 Sep 29; 10(18). PMID: 34575160    Free PMC article.
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang, Goki Suda, +18 authors, Naoya Sakamoto.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008398    Free PMC article.
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Kazuharu Suzuki, Goki Suda, +17 authors, Naoya Sakamoto.
PLoS One, 2022 Jan 21; 17(1). PMID: 35051189    Free PMC article.
Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
Takuya Sho, Kenichi Morikawa, +10 authors, Naoya Sakamoto.
World J Gastrointest Oncol, 2022 Jan 25; 13(12). PMID: 35070043    Free PMC article.
Review.
Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong Dong, Jin-Yu Shi, +4 authors, Nan-Ya Wang.
Medicine (Baltimore), 2022 Feb 05; 101(5). PMID: 35119010    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.